Table 3 Univariate analysis for fracture-free survival in patients who received curettage for GCTBs of the extremities
From: Risk factors of fracture following curettage for bone giant cell tumors of the extremities
Variable | No. of patients (n = 284) | 1-year fracture-free survival (95% CI) (%) | P value |
|---|---|---|---|
Sex | 0.707 | ||
 Male | 131 | 96.9 (92.1–98.8) |  |
 Female | 153 | 97.4 (93.2–99.0) |  |
Age (years) | 0.978 | ||
  < 30 | 140 | 97.1 (92.6–98.9) |  |
  ≥ 30 | 144 | 97.2 (92.8–99.0) |  |
Site | 0.0005a | ||
 Femur | 107 | 92.5 (85.8–96.2) |  |
 Others | 177 | 100.0 |  |
Campanacci classification | 0.424 | ||
 Stage I, II | 227 | 96.9 (93.7–98.5) |  |
 Stage III | 57 | 98.2 (88.6–99.8) |  |
Pathological fracture at presentation | 0.048a | ||
 No | 267 | 97.8 (95.1–99.0) |  |
 Yes | 17 | 88.2 (63.2–97.0) |  |
Denosumab administration | 0.952 | ||
 No | 254 | 97.2 (94.3–98.7) |  |
 Yes | 30 | 96.7 (79.8–99.5) |  |
Previous surgery | 0.858 | ||
 No | 251 | 96.8 (93.8–98.4) |  |
 Yes | 33 | 100.0 |  |
Bone grafting | 0.003a | ||
 No | 125 | 94.4 (88.7–97.3) |  |
 Yes | 159 | 99.4 (95.7–99.9) |  |
Local adjuvant therapy | 0.502 | ||
 No | 37 | 94.6 (80.8–98.6) |  |
 Yes | 247 | 97.6 (94.7–98.9) |  |